MAFK — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL18937400	0.47	2/20
SCHEMBL3811926	0.47	2/20
SCHEMBL1688838	0.45	2/20
SCHEMBL4859085	0.45	2/20
SCHEMBL14268358	0.45	2/20
SCHEMBL14268360	0.45	2/20
Butyl Isothiocyanate (SCHEMBL28841563)	0.45	2/20
SCHEMBL18911845	0.45	2/20
SCHEMBL988586	0.44	2/20
SCHEMBL6384757	0.39	2/20
SCHEMBL18905760	0.39	2/20
Butyl Isothiocyanate (SCHEMBL28493037)	0.39	2/20
SCHEMBL10045193	0.37	2/20
Butyl Isothiocyanate (SCHEMBL8186071)	0.36	2/20
SCHEMBL18911841	0.36	2/20
SCHEMBL484045	0.56	1/20
SCHEMBL21842754	0.56	1/20
SCHEMBL21842756	0.54	1/20
SCHEMBL330913	0.54	1/20
SCHEMBL1233523	0.54	1/20

Clinical trials — most relevant to MAFK by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Compare the Impact of Xuezhikang and Atorvastatin on Glucose Metabolism in Dyslipidemia Patients With Prediabetes	PHASE4	COMPLETED
Role of Pioglitazone in the Treatment of Non-alcoholic Steatohepatitis (NASH)	PHASE4	COMPLETED
Strategies to Reduce Organic Muscle Atrophy in the Intensive Care Unit	PHASE2/PHASE3	WITHDRAWN
Efficacy and Safety of Pioglitazone and Metformin Combination Therapy in Treating Type 2 Diabetes Mellitus.	PHASE3	COMPLETED
Efficacy and Safety of Oral Immunotherapy With GcMAF in Hospitalized Patients With COVID-19 Pneumonia	PHASE2	COMPLETED
Metformin for Fibromyalgia Symptoms (INFORM Trial)	PHASE2	RECRUITING
Effect of CoQ10 on the Outcome of MAFLD Patients	PHASE2	RECRUITING
A Study of Bezafibrate in Mitochondrial Myopathy	PHASE2	COMPLETED
Mitochondrial Activity and Myosteatosis in the Cachexia of Cancers of the Upper Aerodigestive Tract	nan	UNKNOWN
Prehabilitation in Older People Undergoing Total Hip Replacement	nan	NOT_YET_RECRUITING
Combining Gene Variants to Improve Risk Prediction for Metabolic (Dysfunction)- Associated Fatty Liver Disease and Its Progression to Cirrhosis in Indian Individuals With Type 2 Diabetes	nan	COMPLETED
Calorie Restriction in Multiple Sclerosis	nan	ACTIVE_NOT_RECRUITING
Impact Of Choline in Patients With NAFLD	nan	UNKNOWN
Mechanisms of Insulin Resistance in Humans	nan	COMPLETED
A Pilot Study of Berberine (Soloways ™) in Patients with Type 2 Diabetes Mellitus Carrying TCF7L2 Polymorphisms	nan	COMPLETED
Metabolic Signalling in Muscle- and Adipose-tissue Following Insulin Withdrawal and Growth Hormone Injection.	nan	COMPLETED
Abnormalities in the Effects of Insulin and Exercise on Glucose- and Lipid Metabolism in Obesity and Type 2 Diabetes	nan	COMPLETED
Influence of Dietary Fiber-rich Meals on Gene Expression and Postprandial Glucose and Lipid Response	nan	COMPLETED
Evaluation of the Predictive Effect of Inflammatory Markers in MI Patients	nan	UNKNOWN
Recall of a Cohort of Subjects in the Mediterranean Area. Monitoring of Liver Diseases (NUTRIHEP 3).	nan	NOT_YET_RECRUITING
Intestinal Ketone Bodies Interfere With the Glycemic Control	nan	COMPLETED
Thermogenic Silencer Regulatory Factors in Humans	nan	ACTIVE_NOT_RECRUITING
Magnetic Resonance Imaging in Obesity	nan	COMPLETED
The Effects of HER2 Receptor Signaling on Human Brown Fat Activity	nan	RECRUITING
Hypovitaminosis D and Metabolic Inflammatory Status in Patients With Obesity	nan	COMPLETED
Identification and Metabolic Characterization of a Cohort of Human Subjects With Mutations in PRDM-16	nan	COMPLETED
The Impact of Bariatric Surgery on Adipocyte Metabolism	nan	COMPLETED
Oxidative Stress in Intestinal Metaplasia and Metabolic Syndrome	nan	UNKNOWN
Acute Fatty Acid Intervention Study (AFAST)	nan	COMPLETED
Nasturtium (Tropaeolum Majus L) Intake and Biochemical Parameters in Pre-diabetic Subjects in Bogota Colombia	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a MAFK binder may also engage these)

Protein	Name	Similarity
MAFG	Transcription factor MafG	1.000	landscape →
A5PJV0	—	1.000	A5PJV0 →
Q90595	—	1.000	Q90595 →
Q90889	—	1.000	Q90889 →
Q90596	—	1.000	Q90596 →
Q61827	—	1.000	Q61827 →
O54790	—	1.000	O54790 →
Q76MX4	—	0.998	Q76MX4 →
A7YY73	—	0.993	A7YY73 →
O54791	—	0.992	O54791 →
SMARCC2	SWI/SNF complex subunit SMARCC2	0.986	landscape →
F1QW76	—	0.985	F1QW76 →
Q04666	—	0.984	Q04666 →
Q3ZBG4	—	0.984	Q3ZBG4 →
Q90VV1	—	0.983	Q90VV1 →
P35428	—	0.983	P35428 →
Q9ULX9	—	0.983	Q9ULX9 →
Q9D8Y8	—	0.982	Q9D8Y8 →
Q6GN21	—	0.982	Q6GN21 →
Q90Z12	—	0.982	Q90Z12 →
Q03973	—	0.982	Q03973 →
Q6PDG5	—	0.982	Q6PDG5 →
P50538	—	0.982	P50538 →
Q5ZMC9	—	0.982	Q5ZMC9 →
Q9ERR1	—	0.981	Q9ERR1 →
Q01070	—	0.981	Q01070 →
Q8NEN9	—	0.981	Q8NEN9 →
A0M8T5	—	0.981	A0M8T5 →
Q59PR9	—	0.981	Q59PR9 →
Q8CFE3	—	0.981	Q8CFE3 →